Brightsurf Science News & Current Events

September 27, 2015
Atezolizumab set to change refractory lung cancer treatment
Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr.

Two-drug combo helps older adults with hard-to-treat depression
More than half of older adults with clinical depression don't get better when treated with an antidepressant.

Hormonal therapy may prevent ovarian failure and preserve fertility in breast cancer
Young women undergoing chemotherapy for breast cancer may be more likely to remain fertile if they also receive hormonal treatment.

Nivolumab improves the proportion of lung cancer patients alive after more than a year
Updated results from the CheckMate 057 phase III clinical trial show that nivolumab continues to show an overall survival benefit compared to docetaxel in patients with non-squamous non-small cell lung cancer.

Shigeki Watanabe wins 2015 Eppendorf/Science Prize
Shigeki Watanabe is the 2015 grand prize winner in the annual international competition for The Eppendorf & Science Prize for Neurobiology.

Infections in childhood could provide clues to disease development in later life
The interaction between infections and the microbiota during infancy in the lungs could help provide clues to disease development later in life, according to the findings of a new study.

Blocking light improves preemies' survival rates
The survival rate of preemies born between 26 to 31 weeks of gestation is improved by blocking light from reaching the intravenously-fed infused nutritious mixture they depend on for survival, researchers at CHU Sainte-Justine and the University of Montreal have revealed in a new study.

Finding a way to boost efficiency of CIGS solar cells
Toyohashi University of Technology researchers have revealed the structure of the buffer layer in a CIGS (copper-indium-gallium-selenide) solar cell at SPring8, the world's largest third-generation synchrotron radiation facility.

Post-diagnosis aspirin improves survival in all gastrointestinal cancers
Aspirin improves survival in patients with tumors situated throughout the gastrointestinal tract, results from a large study in The Netherlands show.

Differences found between smokers and non-smokers who develop lung cancer
Tobacco smoke is known to be the main risk factor for non-small cell lung cancer (NSCLC), although non-smokers can get it too.

Biomimetic dental prosthesis
ETH material researchers are developing a procedure that allows them to mimic the complex fine structure of biological composite materials, such as teeth or seashells.

The Lancet Respiratory Medicine: First UK Biobank genetic study reveals new associations with lung disease and smoking behavior
New research published in The Lancet Respiratory Medicine and presented at this year's European Respiratory Society meeting in Amsterdam presents the first analyses of genetic data from the UK Biobank that reveal new associations with lung disease and smoking behavior.

Walking quieter routes to work can avoid peaks in air pollution
Commuting to work by walking on quieter side streets rather than main roads can help people avoid exposure to peaks in harmful air pollution, according to new research presented today at the European Respiratory Society's International Congress, 2015.

Prestigious fellowship for Strathclyde physics researcher
A researcher at the University of Strathclyde has secured a prestigious fellowship worth £950,000 for study in the quantum physics -- one of only 10 academics in the UK to do so.

Researchers discover contenders in molecular arms race of major plant disease
Researchers have discovered how a tiny viral protein enables the infection of a complex plant, and the finding could lead to understanding viral diseases in other plants, animals and humans.

Cancer, sinusitis, tinnitus, and exposure to tobacco smoke
Research to be presented tomorrow at the 2015 Annual Meeting & OTO EXPOSM of the American Academy of Otolaryngology--Head and Neck Surgery Foundation (AAO-HNSF) spans across the otolaryngology specialty.

Drug combination improves progression-free survival in melanoma patients
Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone.

Combining 2 targeted therapies results in melanoma patients living significantly longer
Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

AAO-HNSF to build clinical data registry for otolaryngology
During a morning session today at the American Academy of Otolaryngology--Head and Neck Surgery Foundation's Annual Meeting & OTO EXPOSM, James C. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to